<DOC>
	<DOCNO>NCT00487630</DOCNO>
	<brief_summary>Fabry disease ( OMIM 301500 ) X-linked inborn error sphingolipid metabolism result deficiency lysosomal enzyme alpha-galactosidase A. Heterozygous females Fabry disease may symptomatic cardiac , renal cerebrovascular involvement . Clearance Gb3 stabilization renal function demonstrate male patient treated agalsidase beta ( FABRAZYME ) . In contrast , randomize , control study efficacy recombinant alpha-galactosidase A report heterozygote Fabry disease .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Agalsidase Beta Heterozygous Females Fabry Disease</brief_title>
	<detailed_description>The primary objective evaluate cardiac leave ventricular mass ( measure echocardiography unique investigator ) females 15 year age affect Fabry disease receive 70 mg agalsidase beta every week , compare untreated control group match gender age . The secondary objective include evaluation : - leave ventricular posterior wall thickness ( echocardiography ) - interventricular septum thickness ( echocardiography ) - tissue doppler imaging ( myocardial function ) - EKG - creatinaemia - serum cystatin C level - urinary protein/creatinine ratio - microalbuminuria - Gb3 urinary level Evaluation tolerance safety : - Home therapy infusion follow - Vitals - Physical examination - Adverse event - Antibodies level</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Female patient 15 year clinical biological evidence Fabry disease ( GLA gene mutation detect ) Pregnancy Allergy agalsidase beta Congestive heart failure Creatinaemia &gt; 135 Âµmol/l Medical history stroke last year Medical history 2 transient ischemic attack Blood pressure &gt; 160/95 Modification medication treat blood pressure last 3 month enrollment Complete absence clinical biological symptom Weight &gt; 87 kg &lt; 35 kg</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Heterozygous female</keyword>
	<keyword>Cardiomyopathy</keyword>
</DOC>